Development of an enhanced recovery protocol after laser ablation surgery protocol: a preliminary analysis.

IF 2.4 Q2 CLINICAL NEUROLOGY Neuro-oncology practice Pub Date : 2023-02-03 eCollection Date: 2023-06-01 DOI:10.1093/nop/npad007
Adam S Levy, Martin A Merenzon, Tiffany Eatz, Alexis A Morell, Daniel G Eichberg, Marc J Bloom, Ashish H Shah, Ricardo J Komotar, Michael E Ivan
{"title":"Development of an enhanced recovery protocol after laser ablation surgery protocol: a preliminary analysis.","authors":"Adam S Levy, Martin A Merenzon, Tiffany Eatz, Alexis A Morell, Daniel G Eichberg, Marc J Bloom, Ashish H Shah, Ricardo J Komotar, Michael E Ivan","doi":"10.1093/nop/npad007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Enhanced recovery after surgery (ERAS) programs are a model of care that aim to improve patient outcomes, reduce complications, and facilitate recovery while reducing healthcare-associated costs and admission length. While such programs have been developed in other surgical subspecialties, there have yet to be guidelines published specifically for laser interstitial thermal therapy (LITT). Here we describe the first multidisciplinary ERAS preliminary protocol for LITT for the treatment of brain tumors.</p><p><strong>Methods: </strong>Between the years 2013 and 2021, 184 adult patients consecutively treated with LITT at our single institution were retrospectively analyzed. During this time, a series of pre, intra, and postoperative adjustments were made to the admission course and surgical/anesthesia workflow with the goal of improving recovery and admission length.</p><p><strong>Results: </strong>The mean age at surgery was 60.7 years with a median preoperative Karnofsky performance score of 90 ± 13. Lesions were most commonly metastases (50%) and high-grade gliomas (37%). The mean length of stay was 2.4 days, with the average patient being discharged 1.2 days after surgery. There was an overall readmission rate of 8.7% with a LITT-specific readmission rate of 2.2%. Three of 184 patients required repeat intervention in the perioperative period, and there was one perioperative mortality.</p><p><strong>Conclusions: </strong>This preliminary study shows the proposed LITT ERAS protocol to be a safe means of discharging patients on postoperative day 1 while preserving outcomes. Although future prospective work is needed to validate this protocol, results show the ERAS approach to be promising for LITT.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"281-290"},"PeriodicalIF":2.4000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180378/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npad007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Enhanced recovery after surgery (ERAS) programs are a model of care that aim to improve patient outcomes, reduce complications, and facilitate recovery while reducing healthcare-associated costs and admission length. While such programs have been developed in other surgical subspecialties, there have yet to be guidelines published specifically for laser interstitial thermal therapy (LITT). Here we describe the first multidisciplinary ERAS preliminary protocol for LITT for the treatment of brain tumors.

Methods: Between the years 2013 and 2021, 184 adult patients consecutively treated with LITT at our single institution were retrospectively analyzed. During this time, a series of pre, intra, and postoperative adjustments were made to the admission course and surgical/anesthesia workflow with the goal of improving recovery and admission length.

Results: The mean age at surgery was 60.7 years with a median preoperative Karnofsky performance score of 90 ± 13. Lesions were most commonly metastases (50%) and high-grade gliomas (37%). The mean length of stay was 2.4 days, with the average patient being discharged 1.2 days after surgery. There was an overall readmission rate of 8.7% with a LITT-specific readmission rate of 2.2%. Three of 184 patients required repeat intervention in the perioperative period, and there was one perioperative mortality.

Conclusions: This preliminary study shows the proposed LITT ERAS protocol to be a safe means of discharging patients on postoperative day 1 while preserving outcomes. Although future prospective work is needed to validate this protocol, results show the ERAS approach to be promising for LITT.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
制定激光烧蚀手术后的强化恢复方案:初步分析。
背景:加强术后恢复(ERAS)计划是一种护理模式,旨在改善患者预后、减少并发症、促进恢复,同时降低医疗相关费用和缩短入院时间。虽然此类项目已在其他外科亚专科中开展,但还没有专门针对激光间质热疗(LITT)的指南。在此,我们介绍了首个用于治疗脑肿瘤的激光间质热疗的多学科 ERAS 初步方案:方法:我们对 2013 年至 2021 年间在本院连续接受 LITT 治疗的 184 名成人患者进行了回顾性分析。在此期间,我们对入院流程和手术/麻醉工作流程进行了一系列术前、术中和术后调整,目的是改善患者的恢复和入院时间:手术时的平均年龄为 60.7 岁,术前 Karnofsky 评分中位数为 90±13 分。病变最常见的是转移瘤(50%)和高级别胶质瘤(37%)。平均住院时间为2.4天,患者平均在术后1.2天出院。总的再入院率为8.7%,LITT特异性再入院率为2.2%。184例患者中有3例需要在围手术期再次进行干预,1例围手术期死亡:这项初步研究表明,建议的 LITT ERAS 方案是一种在术后第 1 天让患者出院的安全方法,同时还能保证疗效。虽然还需要未来的前瞻性工作来验证该方案,但结果表明 ERAS 方法在 LITT 中的应用前景广阔。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
期刊最新文献
Foreword. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Financial challenges of being on long-term, high-cost medications. How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma? Vorasidenib: Patient and caregiver information sheet.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1